BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Martin M, Pienkowski T, Mackey J, Pawlicki M, Guastalla JP, Weaver C, Tomiak E, Al-Tweigeri T, Chap L, Juhos E. Adjuvant docetaxel for node-positive breast cancer. N Engl J Med. 2005;352:2302-2313. [PMID: 15930421 DOI: 10.1056/nejmoa043681] [Cited by in Crossref: 710] [Cited by in F6Publishing: 161] [Article Influence: 44.4] [Reference Citation Analysis]
Number Citing Articles
1 Tuefferd M, Couturier J, Penault-Llorca F, Vincent-Salomon A, Broët P, Guastalla JP, Allouache D, Combe M, Weber B, Pujade-Lauraine E, Camilleri-Broët S. HER2 status in ovarian carcinomas: a multicenter GINECO study of 320 patients. PLoS One 2007;2:e1138. [PMID: 17987122 DOI: 10.1371/journal.pone.0001138] [Cited by in Crossref: 110] [Cited by in F6Publishing: 79] [Article Influence: 7.9] [Reference Citation Analysis]
2 Ellis GK, Barlow WE, Gralow JR, Hortobagyi GN, Russell CA, Royce ME, Perez EA, Lew D, Livingston RB. Phase III comparison of standard doxorubicin and cyclophosphamide versus weekly doxorubicin and daily oral cyclophosphamide plus granulocyte colony-stimulating factor as neoadjuvant therapy for inflammatory and locally advanced breast cancer: SWOG 0012. J Clin Oncol 2011;29:1014-21. [PMID: 21220618 DOI: 10.1200/JCO.2009.27.6543] [Cited by in Crossref: 45] [Cited by in F6Publishing: 28] [Article Influence: 4.5] [Reference Citation Analysis]
3 Hall E, Cameron D, Waters R, Barrett-Lee P, Ellis P, Russell S, Bliss JM, Hopwood P; TACT Trial Investigators. Comparison of patient reported quality of life and impact of treatment side effects experienced with a taxane-containing regimen and standard anthracycline based chemotherapy for early breast cancer: 6 year results from the UK TACT trial (CRUK/01/001). Eur J Cancer 2014;50:2375-89. [PMID: 25065293 DOI: 10.1016/j.ejca.2014.06.007] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 3.3] [Reference Citation Analysis]
4 Qin YY, Li H, Guo XJ, Ye XF, Wei X, Zhou YH, Zhang XJ, Wang C, Qian W, Lu J, He J. Adjuvant chemotherapy, with or without taxanes, in early or operable breast cancer: a meta-analysis of 19 randomized trials with 30698 patients. PLoS One 2011;6:e26946. [PMID: 22069477 DOI: 10.1371/journal.pone.0026946] [Cited by in Crossref: 40] [Cited by in F6Publishing: 37] [Article Influence: 4.0] [Reference Citation Analysis]
5 Altwairgi AK, Hopman WM, Mates M. Real-world impact of granulocyte-colony stimulating factor on febrile neutropenia. Curr Oncol 2013;20:e171-9. [PMID: 23737687 DOI: 10.3747/co.20.1306] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
6 Miguel RS, López-González AM, Sanchez-Iriso E, Mar J, Cabasés JM. Measuring health-related quality of life in drug clinical trials: is it given due importance? Pharm World Sci 2008;30:154-60. [PMID: 17721699 DOI: 10.1007/s11096-007-9152-9] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]
7 Synnestvedt M, Borgen E, Wist E, Wiedswang G, Weyde K, Risberg T, Kersten C, Mjaaland I, Vindi L, Schirmer C, Nesland JM, Naume B. Disseminated tumor cells as selection marker and monitoring tool for secondary adjuvant treatment in early breast cancer. Descriptive results from an intervention study. BMC Cancer 2012;12:616. [PMID: 23259667 DOI: 10.1186/1471-2407-12-616] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
8 Brito M, Esteves S, André R, Isidoro M, Moreira A. Comparison of effectiveness of biosimilar filgrastim (Nivestim™), reference Amgen filgrastim and pegfilgrastim in febrile neutropenia primary prevention in breast cancer patients treated with neo(adjuvant) TAC: a non-interventional cohort study. Support Care Cancer 2016;24:597-603. [PMID: 26111956 DOI: 10.1007/s00520-015-2818-2] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 2.2] [Reference Citation Analysis]
9 Goldstein LJ, Gray R, Badve S, Childs BH, Yoshizawa C, Rowley S, Shak S, Baehner FL, Ravdin PM, Davidson NE. Prognostic utility of the 21-gene assay in hormone receptor-positive operable breast cancer compared with classical clinicopathologic features. J Clin Oncol. 2008;26:4063-4071. [PMID: 18678838 DOI: 10.1200/jco.2007.14.4501] [Cited by in Crossref: 241] [Cited by in F6Publishing: 102] [Article Influence: 18.5] [Reference Citation Analysis]
10 Baur M, van Oosterom AT, Diéras V, Tubiana-Hulin M, Coombes RC, Hatschek T, Murawsky M, Klink-Alakl M, Hudec M, Dittrich C. A phase II trial of docetaxel (Taxotere) as second-line chemotherapy in patients with metastatic breast cancer. J Cancer Res Clin Oncol 2008;134:125-35. [PMID: 17636328 DOI: 10.1007/s00432-007-0259-0] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
11 Eisen A, Fletcher GG, Gandhi S, Mates M, Freedman OC, Dent SF, Trudeau ME; members of the Early Breast Cancer Systemic Therapy Consensus Panel. Optimal systemic therapy for early breast cancer in women: a clinical practice guideline. Curr Oncol 2015;22:S67-81. [PMID: 25848340 DOI: 10.3747/co.22.2320] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 3.7] [Reference Citation Analysis]
12 Burkard ME, Wisinski KB, Njiaju UO, Donohue S, Hegeman R, Stella A, Mansky P, Shah V, Goggins T, Qamar R, Dietrich L, Kim K, Traynor AM, Tevaarwerk AJ. Feasibility of 4 cycles of docetaxel and cyclophosphamide every 14 days as an adjuvant regimen for breast cancer: a Wisconsin Oncology Network study. Clin Breast Cancer 2014;14:205-11. [PMID: 24342730 DOI: 10.1016/j.clbc.2013.10.018] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
13 Fujii T, Le Du F, Xiao L, Kogawa T, Barcenas CH, Alvarez RH, Valero V, Shen Y, Ueno NT. Effectiveness of an Adjuvant Chemotherapy Regimen for Early-Stage Breast Cancer: A Systematic Review and Network Meta-analysis. JAMA Oncol 2015;1:1311-8. [PMID: 26402167 DOI: 10.1001/jamaoncol.2015.3062] [Cited by in Crossref: 41] [Cited by in F6Publishing: 34] [Article Influence: 8.2] [Reference Citation Analysis]
14 Jacquemier J, Boher JM, Roche H, Esterni B, Serin D, Kerbrat P, Andre F, Finetti P, Charafe-Jauffret E, Martin AL, Campone M, Viens P, Birnbaum D, Penault-Llorca F, Bertucci F. Protein expression, survival and docetaxel benefit in node-positive breast cancer treated with adjuvant chemotherapy in the FNCLCC-PACS 01 randomized trial. Breast Cancer Res 2011;13:R109. [PMID: 22044691 DOI: 10.1186/bcr3051] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
15 Dietrich D, Krispin M, Dietrich J, Fassbender A, Lewin J, Harbeck N, Schmitt M, Eppenberger-Castori S, Vuaroqueaux V, Spyratos F. CDO1 promoter methylation is a biomarker for outcome prediction of anthracycline treated, estrogen receptor-positive, lymph node-positive breast cancer patients. BMC Cancer. 2010;10:247. [PMID: 20515469 DOI: 10.1186/1471-2407-10-247] [Cited by in Crossref: 30] [Cited by in F6Publishing: 33] [Article Influence: 2.7] [Reference Citation Analysis]
16 Prieto-Callejero B, Rivera F, Andrés-Villas M, Gómez-Salgado J. Influence of the Sense of Coherence, the Doctor-Patient Relationship, Optimism and Non-Haematological Adverse Reactions on Health-Related Quality of Life in Patients with Breast Cancer. J Clin Med 2019;8:E2043. [PMID: 31766496 DOI: 10.3390/jcm8122043] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
17 Nomura H, Aoki D, Michimae H, Mizuno M, Nakai H, Arai M, Sasagawa M, Ushijima K, Sugiyama T, Saito M, Tokunaga H, Matoda M, Nakanishi T, Watanabe Y, Takahashi F, Saito T, Yaegashi N; Japanese Gynecologic Oncology Group. Effect of Taxane Plus Platinum Regimens vs Doxorubicin Plus Cisplatin as Adjuvant Chemotherapy for Endometrial Cancer at a High Risk of Progression: A Randomized Clinical Trial. JAMA Oncol 2019;5:833-40. [PMID: 30896757 DOI: 10.1001/jamaoncol.2019.0001] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 17.0] [Reference Citation Analysis]
18 Ho MY, Mackey JR. Presentation and management of docetaxel-related adverse effects in patients with breast cancer. Cancer Manag Res 2014;6:253-9. [PMID: 24904223 DOI: 10.2147/CMAR.S40601] [Cited by in Crossref: 77] [Cited by in F6Publishing: 26] [Article Influence: 11.0] [Reference Citation Analysis]
19 Dörfel S, Steffens CC, Meyer D, Tesch H, Kruggel L, Frank M, Jänicke M, Marschner N; TMK-Group (Tumour Registry Breast Cancer). Adjuvant chemotherapeutic treatment of 1650 patients with early breast cancer in routine care in Germany: data from the prospective TMK cohort study. Breast Cancer 2018;25:275-83. [PMID: 29204847 DOI: 10.1007/s12282-017-0823-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
20 Kümmel S, Krocker J, Kohls A, Breitbach GP, Morack G, Budner M, Blohmer JU, Elling D. Randomised trial: survival benefit and safety of adjuvant dose-dense chemotherapy for node-positive breast cancer. Br J Cancer 2006;94:1237-44. [PMID: 16622463 DOI: 10.1038/sj.bjc.6603085] [Cited by in Crossref: 40] [Cited by in F6Publishing: 29] [Article Influence: 2.7] [Reference Citation Analysis]
21 McArthur HL, Rugo H, Nulsen B, Hawks L, Grothusen J, Melisko M, Moasser M, Paulson M, Traina T, Patil S, Zhou Q, Steingart R, Dang C, Morrow M, Cordeiro P, Fornier M, Park J, Seidman A, Lake D, Gilewski T, Theodoulou M, Modi S, D'Andrea G, Sklarin N, Robson M, Moynahan ME, Sugarman S, Sealey JE, Laragh JH, Merali C, Norton L, Hudis CA, Dickler MN. A feasibility study of bevacizumab plus dose-dense doxorubicin-cyclophosphamide (AC) followed by nanoparticle albumin-bound paclitaxel in early-stage breast cancer. Clin Cancer Res 2011;17:3398-407. [PMID: 21350003 DOI: 10.1158/1078-0432.CCR-10-1969] [Cited by in Crossref: 24] [Cited by in F6Publishing: 11] [Article Influence: 2.4] [Reference Citation Analysis]
22 Koizumi W, Kim YH, Fujii M, Kim HK, Imamura H, Lee KH, Hara T, Chung HC, Satoh T, Cho JY, Hosaka H, Tsuji A, Takagane A, Inokuchi M, Tanabe K, Okuno T, Ogura M, Yoshida K, Takeuchi M, Nakajima T; JACCRO and KCSG Study Group. Addition of docetaxel to S-1 without platinum prolongs survival of patients with advanced gastric cancer: a randomized study (START). J Cancer Res Clin Oncol 2014;140:319-28. [PMID: 24366758 DOI: 10.1007/s00432-013-1563-5] [Cited by in Crossref: 97] [Cited by in F6Publishing: 86] [Article Influence: 12.1] [Reference Citation Analysis]
23 Mittendorf EA, Jeruss JS, Tucker SL, Kolli A, Newman LA, Gonzalez-Angulo AM, Buchholz TA, Sahin AA, Cormier JN, Buzdar AU, Hortobagyi GN, Hunt KK. Validation of a novel staging system for disease-specific survival in patients with breast cancer treated with neoadjuvant chemotherapy. J Clin Oncol 2011;29:1956-62. [PMID: 21482989 DOI: 10.1200/JCO.2010.31.8469] [Cited by in Crossref: 86] [Cited by in F6Publishing: 27] [Article Influence: 8.6] [Reference Citation Analysis]
24 Nieto Y, Aramendía JM, Espinós J, De la Cruz S, Fernández-Hidalgo O, Santisteban M, Arbea L, Aristu J, Martínez-Monge R, Moreno M, Pina L, Sola J, Zornoza G, Regueira FM. Sequential administration of dose-dense epirubicin/cyclophosphamide followed by docetaxel/capecitabine for patients with HER2-negative and locally advanced or node-positive breast cancer. Cancer Chemother Pharmacol 2010;65:457-65. [PMID: 19526361 DOI: 10.1007/s00280-009-1049-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
25 Vaz-Luis I, Winer EP, Lin NU. Human epidermal growth factor receptor-2-positive breast cancer: does estrogen receptor status define two distinct subtypes? Ann Oncol 2013;24:283-91. [PMID: 23022997 DOI: 10.1093/annonc/mds286] [Cited by in Crossref: 37] [Cited by in F6Publishing: 35] [Article Influence: 4.1] [Reference Citation Analysis]
26 Bae JH, Baek YH, Lee JE, Song I, Lee JH, Shin JY. Machine Learning for Detection of Safety Signals From Spontaneous Reporting System Data: Example of Nivolumab and Docetaxel. Front Pharmacol 2020;11:602365. [PMID: 33628176 DOI: 10.3389/fphar.2020.602365] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
27 Suzuki Y, Saeki T, Aogi K, Toi M, Fujii H, Inoue K, Watanabe T, Fujiwara Y, Ito Y, Takatsuka Y, Iwata H, Arioka H, Tokuda Y. A multicenter phase II study of TSU-68, a novel oral multiple tyrosine kinase inhibitor, in patients with metastatic breast cancer progressing despite prior treatment with an anthracycline-containing regimen and taxane. Int J Clin Oncol 2013;18:590-7. [PMID: 22585426 DOI: 10.1007/s10147-012-0421-9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
28 Fernández-Cuesta L, Oakman C, Falagan-Lotsch P, Smoth KS, Quinaux E, Buyse M, Dolci MS, Azambuja ED, Hainaut P, Dell'orto P, Larsimont D, Francis PA, Crown J, Piccart-Gebhart M, Viale G, Leo AD, Olivier M. Prognostic and predictive value of TP53 mutations in node-positive breast cancer patients treated with anthracycline- or anthracycline/taxane-based adjuvant therapy: results from the BIG 02-98 phase III trial. Breast Cancer Res 2012;14:R70. [PMID: 22551440 DOI: 10.1186/bcr3179] [Cited by in Crossref: 48] [Cited by in F6Publishing: 38] [Article Influence: 5.3] [Reference Citation Analysis]
29 Cameron D. Management of chemotherapy-associated febrile neutropenia. Br J Cancer 2009;101 Suppl 1:S18-22. [PMID: 19756002 DOI: 10.1038/sj.bjc.6605272] [Cited by in Crossref: 32] [Cited by in F6Publishing: 25] [Article Influence: 2.7] [Reference Citation Analysis]
30 Kim SB, Kok YT, Thuan TV, Chao TY, Shen ZZ. Safety Results of Docetaxel-(Taxotere®)-Based Chemotherapy in Early Breast Cancer Patients of Asia-Pacific Region: Asia-Pacific Breast Initiative II. J Breast Cancer 2015;18:356-64. [PMID: 26770242 DOI: 10.4048/jbc.2015.18.4.356] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
31 Vici P, Brandi M, Giotta F, Foggi P, Schittulli F, Di Lauro L, Gebbia N, Massidda B, Filippelli G, Giannarelli D, Di Benedetto A, Mottolese M, Colucci G, Lopez M. A multicenter phase III prospective randomized trial of high-dose epirubicin in combination with cyclophosphamide (EC) versus docetaxel followed by EC in node-positive breast cancer. GOIM (Gruppo Oncologico Italia Meridionale) 9902 study. Ann Oncol 2012;23:1121-9. [PMID: 21965475 DOI: 10.1093/annonc/mdr412] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
32 Nair P, Prado M, Perea-Gil I, Karakikes I. Concise Review: Precision Matchmaking: Induced Pluripotent Stem Cells Meet Cardio-Oncology. Stem Cells Transl Med 2019;8:758-67. [PMID: 31020786 DOI: 10.1002/sctm.18-0279] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
33 García-Mata J, García-Palomo A, Calvo L, Mel R, Cruz JJ, Ramos M. Phase II study of dose-dense doxorubicin and docetaxel as neoadjunvant chemotherapy with G-CSF support in patients with large or locally advanced breast cancer. Clin Transl Oncol 2008;10:739-44. [PMID: 19015070 DOI: 10.1007/s12094-008-0280-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
34 Thornton LM, Carson WE 3rd, Shapiro CL, Farrar WB, Andersen BL. Delayed emotional recovery after taxane-based chemotherapy. Cancer 2008;113:638-47. [PMID: 18521922 DOI: 10.1002/cncr.23589] [Cited by in Crossref: 37] [Cited by in F6Publishing: 32] [Article Influence: 2.8] [Reference Citation Analysis]
35 Trentham-Dietz A, Sprague BL, Klein R, Klein BE, Cruickshanks KJ, Fryback DG, Hampton JM. Health-related quality of life before and after a breast cancer diagnosis. Breast Cancer Res Treat 2008;109:379-87. [PMID: 17674200 DOI: 10.1007/s10549-007-9653-1] [Cited by in Crossref: 48] [Cited by in F6Publishing: 43] [Article Influence: 3.4] [Reference Citation Analysis]
36 Ginés J, Sabater E, Martorell C, Grau M, Monroy M, Casado MA. Efficacy of taxanes as adjuvant treatment of breast cancer: a review and meta-analysis of randomised clinical trials. Clin Transl Oncol 2011;13:485-98. [PMID: 21775276 DOI: 10.1007/s12094-011-0686-x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 1.9] [Reference Citation Analysis]
37 Masuda N, Tokuda Y, Nakamura S, Shimazaki R, Ito Y, Tamura K. Dose response of pegfilgrastim in Japanese breast cancer patients receiving six cycles of docetaxel, doxorubicin, and cyclophosphamide therapy: a randomized controlled trial. Support Care Cancer 2015;23:2891-8. [PMID: 25733000 DOI: 10.1007/s00520-015-2654-4] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
38 Schönherr A, Aivazova-Fuchs V, Annecke K, Jückstock J, Hepp P, Andergassen U, Augustin D, Simon W, Wischnik A, Mohrmann S, Salmen J, Zwingers T, Kiechle M, Harbeck N, Friese K, Janni W, Rack B. Toxicity Analysis in the ADEBAR Trial: Sequential Anthracycline-Taxane Therapy Compared with FEC120 for the Adjuvant Treatment of High-Risk Breast Cancer. Breast Care (Basel) 2012;7:289-95. [PMID: 23904831 DOI: 10.1159/000341384] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
39 Oakman C, Bessi S, Zafarana E, Galardi F, Biganzoli L, Di Leo A. Recent advances in systemic therapy: new diagnostics and biological predictors of outcome in early breast cancer. Breast Cancer Res 2009;11:205. [PMID: 19435470 DOI: 10.1186/bcr2238] [Cited by in Crossref: 54] [Cited by in F6Publishing: 46] [Article Influence: 4.5] [Reference Citation Analysis]
40 Martín M, de la Torre-Montero JC, López-Tarruella S, Pinilla K, Casado A, Fernandez S, Jerez Y, Puente J, Palomero I, González Del Val R, Del Monte-Millan M, Massarrah T, Vila C, García-Paredes B, García-Sáenz JA, Lluch A. Persistent major alopecia following adjuvant docetaxel for breast cancer: incidence, characteristics, and prevention with scalp cooling. Breast Cancer Res Treat 2018;171:627-34. [PMID: 29923063 DOI: 10.1007/s10549-018-4855-2] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
41 Minami CA, Chung DU, Chang HR. Management options in triple-negative breast cancer. Breast Cancer (Auckl) 2011;5:175-99. [PMID: 21863131 DOI: 10.4137/BCBCR.S6562] [Cited by in Crossref: 8] [Cited by in F6Publishing: 16] [Article Influence: 0.8] [Reference Citation Analysis]
42 Tsai CJ, Li J, Gonzalez-Angulo AM, Allen PK, Woodward WA, Ueno NT, Lucci A, Krishnamurthy S, Gong Y, Yang W, Cristofanilli M, Valero V, Buchholz TA. Outcomes After Multidisciplinary Treatment of Inflammatory Breast Cancer in the Era of Neoadjuvant HER2-directed Therapy. Am J Clin Oncol 2015;38:242-7. [PMID: 23648437 DOI: 10.1097/COC.0b013e3182937921] [Cited by in Crossref: 15] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
43 Ishigami E, Sakakibara M, Sakakibara J, Iwase T, Hayama S, Masuda T, Nakagawa A, Nagashima T, Sangai T, Fujimoto H, Otsuka M. Phase II study of neoadjuvant anthracycline combined with nanoparticle albumin-bound paclitaxel for human epidermal growth factor receptor 2-negative breast cancer. Mol Clin Oncol 2017;7:1079-82. [PMID: 29285378 DOI: 10.3892/mco.2017.1464] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
44 Penault-Llorca F, Filleron T, Asselain B, Baehner FL, Fumoleau P, Lacroix-Triki M, Anderson JM, Yoshizawa C, Cherbavaz DB, Shak S, Roca L, Sagan C, Lemonnier J, Martin AL, Roché H. The 21-gene Recurrence Score® assay predicts distant recurrence in lymph node-positive, hormone receptor-positive, breast cancer patients treated with adjuvant sequential epirubicin- and docetaxel-based or epirubicin-based chemotherapy (PACS-01 trial). BMC Cancer 2018;18:526. [PMID: 29728098 DOI: 10.1186/s12885-018-4331-8] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
45 Zhou W, Ding Q, Liang X, He Z, Zha X, Liu X, Wang S. The risk of amenorrhea is related to chemotherapy-induced leucopenia in breast cancer patients receiving epirubicin and taxane based chemotherapy. PLoS One 2012;7:e37249. [PMID: 22615953 DOI: 10.1371/journal.pone.0037249] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
46 Sung M, Giannakakou P. BRCA1 regulates microtubule dynamics and taxane-induced apoptotic cell signaling. Oncogene 2014;33:1418-28. [PMID: 23524581 DOI: 10.1038/onc.2013.85] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 4.3] [Reference Citation Analysis]
47 Morden JP, Alvarez I, Bertelli G, Coates AS, Coleman R, Fallowfield L, Jassem J, Jones S, Kilburn L, Lønning PE, Ortmann O, Snowdon C, van de Velde C, Andersen J, Del Mastro L, Dodwell D, Holmberg S, Nicholas H, Paridaens R, Bliss JM, Coombes RC. Long-Term Follow-Up of the Intergroup Exemestane Study. J Clin Oncol 2017;35:2507-14. [PMID: 28467729 DOI: 10.1200/JCO.2016.70.5640] [Cited by in Crossref: 10] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
48 Kulkarni SA, Hicks DG, Watroba NL, Murekeyisoni C, Hwang H, Khoury T, Beck RA, Ring BZ, Estopinal NC, Schreeder MT, Seitz RS, Ross DT. TLE3 as a candidate biomarker of response to taxane therapy. Breast Cancer Res 2009;11:R17. [PMID: 19309506 DOI: 10.1186/bcr2241] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 1.8] [Reference Citation Analysis]
49 Ellis P, Barrett-Lee P, Johnson L, Cameron D, Wardley A, O'Reilly S, Verrill M, Smith I, Yarnold J, Coleman R, Earl H, Canney P, Twelves C, Poole C, Bloomfield D, Hopwood P, Johnston S, Dowsett M, Bartlett JM, Ellis I, Peckitt C, Hall E, Bliss JM; TACT Trial Management Group., TACT Trialists. Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trial. Lancet 2009;373:1681-92. [PMID: 19447249 DOI: 10.1016/S0140-6736(09)60740-6] [Cited by in Crossref: 133] [Cited by in F6Publishing: 46] [Article Influence: 11.1] [Reference Citation Analysis]
50 Martin M, Ramos-Medina R, Bernat R, García-Saenz JA, Del Monte-Millan M, Alvarez E, Cebollero M, Moreno F, Gonzalez-Haba E, Bueno O, Romero P, Massarrah T, Echavarria I, Jerez Y, Herrero B, Gonzalez Del Val R, Lobato N, Rincon P, Palomero MI, Marquez-Rodas I, Lizarraga S, Asensio F, Lopez-Tarruella S. Activity of docetaxel, carboplatin, and doxorubicin in patient-derived triple-negative breast cancer xenografts. Sci Rep 2021;11:7064. [PMID: 33782404 DOI: 10.1038/s41598-021-85962-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
51 Kouroukis CT, Chia S, Verma S, Robson D, Desbiens C, Cripps C, Mikhael J. Canadian supportive care recommendations for the management of neutropenia in patients with cancer. Curr Oncol 2008;15:9-23. [PMID: 18317581 DOI: 10.3747/co.2008.198] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.5] [Reference Citation Analysis]
52 Tudoran O, Soritau O, Balacescu L, Visan S, Barbos O, Cojocneanu-Petric R, Balacescu O, Berindan-Neagoe I. Regulation of stem cells-related signaling pathways in response to doxorubicin treatment in Hs578T triple-negative breast cancer cells. Mol Cell Biochem 2015;409:163-76. [PMID: 26187676 DOI: 10.1007/s11010-015-2522-z] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
53 Grau JJ, Zanon G, Caso C, Gonzalez X, Rodriguez A, Caballero M, Biete A. Prognosis in women with breast cancer and private extra insurance coverage. Ann Surg Oncol 2013;20:2822-7. [PMID: 23754547 DOI: 10.1245/s10434-013-3025-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
54 Verrill M. Chemotherapy for early-stage breast cancer: a brief history. Br J Cancer 2009;101 Suppl 1:S2-5. [PMID: 19756003 DOI: 10.1038/sj.bjc.6605268] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 1.7] [Reference Citation Analysis]
55 Hugh J, Hanson J, Cheang MC, Nielsen TO, Perou CM, Dumontet C, Reed J, Krajewska M, Treilleux I, Rupin M. Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial. J Clin Oncol. 2009;27:1168-1176. [PMID: 19204205 DOI: 10.1200/jco.2008.18.1024] [Cited by in Crossref: 375] [Cited by in F6Publishing: 150] [Article Influence: 31.3] [Reference Citation Analysis]
56 Schneider BP, Zhao F, Wang M, Stearns V, Martino S, Jones V, Perez EA, Saphner T, Wolff AC, Sledge GW Jr, Wood WC, Davidson NE, Sparano JA. Neuropathy is not associated with clinical outcomes in patients receiving adjuvant taxane-containing therapy for operable breast cancer. J Clin Oncol 2012;30:3051-7. [PMID: 22851566 DOI: 10.1200/JCO.2011.39.8446] [Cited by in Crossref: 59] [Cited by in F6Publishing: 32] [Article Influence: 6.6] [Reference Citation Analysis]
57 Tozuka K, Horiguchi J, Takata D, Rokutanda N, Nagaoka R, Tokiniwa H, Kikuchi M, Satou A, Takei H, Takeyoshi I. Collagen gel droplet-embedded culture-drug sensitivity test and Ki67 expression in estrogen receptor-positive and HER2-negative breast cancer. Mol Clin Oncol 2013;1:93-9. [PMID: 24649129 DOI: 10.3892/mco.2012.4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
58 Hong J, Chen X, Huang J, Li C, Zhong L, Chen L, Wu J, Huang O, He J, Zhu L, Chen W, Li Y, Wan H, Shen K. Danggui Buxue Decoction, a Classical Formula of Traditional Chinese Medicine, Fails to Prevent Myelosuppression in Breast Cancer Patients Treated With Adjuvant Chemotherapy: A Prospective Study. Integr Cancer Ther 2017;16:406-13. [PMID: 28818031 DOI: 10.1177/1534735416675952] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
59 Chew HK, Doroshow JH, Frankel P, Margolin KA, Somlo G, Lenz HJ, Gordon M, Zhang W, Yang D, Russell C, Spicer D, Synold T, Bayer R, Hantel A, Stiff PJ, Tetef ML, Gandara DR, Albain KS. Phase II studies of gemcitabine and cisplatin in heavily and minimally pretreated metastatic breast cancer. J Clin Oncol 2009;27:2163-9. [PMID: 19307510 DOI: 10.1200/JCO.2008.17.4839] [Cited by in Crossref: 50] [Cited by in F6Publishing: 16] [Article Influence: 4.2] [Reference Citation Analysis]
60 Zhang W, Jiang Z, Wang L, Li C, Xia J. An open-label, randomized, multicenter dose-finding study of once-per-cycle pegfilgrastim versus daily filgrastim in Chinese breast cancer patients receiving TAC chemotherapy. Med Oncol 2015;32:147. [PMID: 25820754 DOI: 10.1007/s12032-015-0537-7] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
61 Brown T, Sykes D, Allen AR. Implications of Breast Cancer Chemotherapy-Induced Inflammation on the Gut, Liver, and Central Nervous System. Biomedicines 2021;9:189. [PMID: 33668580 DOI: 10.3390/biomedicines9020189] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
62 Alken S, Kelly CM. Benefit risk assessment and update on the use of docetaxel in the management of breast cancer. Cancer Manag Res 2013;5:357-65. [PMID: 24143122 DOI: 10.2147/CMAR.S49321] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
63 Jiang Y, Lin N, Huang S, Lin C, Jin N, Zhang Z, Ke J, Yu Y, Zhu J, Wang Y. Tracking nonpalpable breast cancer for breast-conserving surgery with carbon nanoparticles: implication in tumor location and lymph node dissection. Medicine (Baltimore) 2015;94:e605. [PMID: 25761181 DOI: 10.1097/MD.0000000000000605] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
64 Chu QD, Peddi P. Should Sentinel Lymph Node Biopsy for Patients with Early Breast Cancer Be Abandoned? Not So Fast. Clin Med Insights Oncol 2016;10:67-9. [PMID: 27398043 DOI: 10.4137/CMO.S32817] [Reference Citation Analysis]
65 Jimenez P, Pathak A, Phan AT. The role of taxanes in the management of gastroesphageal cancer. J Gastrointest Oncol 2011;2:240-9. [PMID: 22811858 DOI: 10.3978/j.issn.2078-6891.2011.027] [Cited by in F6Publishing: 9] [Reference Citation Analysis]
66 Connolly RM, Rudek MA, Garrett-Mayer E, Jeter SC, Donehower MG, Wright LA, Zhao M, Fetting JH, Emens LA, Stearns V, Davidson NE, Baker SD, Wolff AC. Docetaxel metabolism is not altered by imatinib: findings from an early phase study in metastatic breast cancer. Breast Cancer Res Treat 2011;127:153-62. [PMID: 21350820 DOI: 10.1007/s10549-011-1413-6] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.5] [Reference Citation Analysis]
67 Song H, Shahverdi K, Huso DL, Esaias C, Fox J, Liedy A, Zhang Z, Reilly RT, Apostolidis C, Morgenstern A, Sgouros G. 213Bi (alpha-emitter)-antibody targeting of breast cancer metastases in the neu-N transgenic mouse model. Cancer Res 2008;68:3873-80. [PMID: 18483272 DOI: 10.1158/0008-5472.CAN-07-6308] [Cited by in Crossref: 39] [Cited by in F6Publishing: 24] [Article Influence: 3.0] [Reference Citation Analysis]
68 Koutras AK, Kalogeras KT, Dimopoulos MA, Wirtz RM, Dafni U, Briasoulis E, Pectasides D, Gogas H, Christodoulou C, Aravantinos G, Zografos G, Timotheadou E, Papakostas P, Linardou H, Razis E, Economopoulos T, Kalofonos HP, Fountzilas G; Hellenic Cooperative Oncology Group (HeCOG). Evaluation of the prognostic and predictive value of HER family mRNA expression in high-risk early breast cancer: a Hellenic Cooperative Oncology Group (HeCOG) study. Br J Cancer 2008;99:1775-85. [PMID: 18985033 DOI: 10.1038/sj.bjc.6604769] [Cited by in Crossref: 43] [Cited by in F6Publishing: 37] [Article Influence: 3.3] [Reference Citation Analysis]
69 Jacobs C, Hutton B, Mazzarello S, Smith S, Joy A, Amir E, Ibrahim MF, Gregario N, Daigle K, Eggert L, Clemons M. Optimisation of steroid prophylaxis schedules in breast cancer patients receiving docetaxel chemotherapy-a survey of health care providers and patients. Support Care Cancer 2015;23:3269-75. [PMID: 25933700 DOI: 10.1007/s00520-015-2731-8] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 2.2] [Reference Citation Analysis]
70 Li Y, Chen M, Pardini B, Dragomir MP, Lucci A, Calin GA. The role of radiotherapy in metaplastic breast cancer: a propensity score-matched analysis of the SEER database. J Transl Med 2019;17:318. [PMID: 31547814 DOI: 10.1186/s12967-019-2069-y] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
71 Vilarino-Varela M, Chin YS, Makris A. Current indications for post-mastectomy radiation. Int Semin Surg Oncol 2009;6:5. [PMID: 19203387 DOI: 10.1186/1477-7800-6-5] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
72 Lopez P, Galvão DA, Taaffe DR, Newton RU, Souza G, Trajano GS, Pinto RS. Resistance training in breast cancer patients undergoing primary treatment: a systematic review and meta-regression of exercise dosage. Breast Cancer 2021;28:16-24. [PMID: 32815096 DOI: 10.1007/s12282-020-01147-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
73 López-Tarruella S, Martín M. Recent advances in systemic therapy: advances in adjuvant systemic chemotherapy of early breast cancer. Breast Cancer Res 2009;11:204. [PMID: 19344489 DOI: 10.1186/bcr2226] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 1.8] [Reference Citation Analysis]
74 Park KH, Lee S, Park JH, Kang SY, Kim HY, Park IH, Park YH, Im YH, Lee HJ, Park S, Lee SI, Jung KH, Kim YS, Seo JH. A randomized, multi-center, open-label, phase III study of once-per-cycle DA-3031, a pegylated G-CSF, in comparison with daily filgrastim in patients receiving TAC chemotherapy for breast cancer. Support Care Cancer 2017;25:505-11. [PMID: 27709313 DOI: 10.1007/s00520-016-3429-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
75 Harris LN, Broadwater G, Lin NU, Miron A, Schnitt SJ, Cowan D, Lara J, Bleiweiss I, Berry D, Ellis M, Hayes DF, Winer EP, Dressler L. Molecular subtypes of breast cancer in relation to paclitaxel response and outcomes in women with metastatic disease: results from CALGB 9342. Breast Cancer Res 2006;8:R66. [PMID: 17129383 DOI: 10.1186/bcr1622] [Cited by in Crossref: 100] [Cited by in F6Publishing: 91] [Article Influence: 7.1] [Reference Citation Analysis]
76 Reinisch M, von Minckwitz G, Harbeck N, Janni W, Kümmel S, Kaufmann M, Elling D, Nekljudova V, Loibl S. Side effects of standard adjuvant and neoadjuvant chemotherapy regimens according to age groups in primary breast cancer. Breast Care (Basel) 2013;8:60-6. [PMID: 24715845 DOI: 10.1159/000346834] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 2.4] [Reference Citation Analysis]
77 Broberg AM, Geisler J, Tuohinen S, Skytta T, Hrafnkelsdóttir ÞJ, Nielsen KM, Hedayati E, Omland T, Offersen BV, Lyon AR, Gulati G. Prevention, Detection, and Management of Heart Failure in Patients Treated for Breast Cancer. Curr Heart Fail Rep 2020;17:397-408. [PMID: 32979150 DOI: 10.1007/s11897-020-00486-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
78 Xu F, Zhang Y, Miao Z, Zeng X, Wu B, Cai L, Liu J, Wang S, Hu X, Zheng W, Chen Z, Yang Q, Jiang Z. Efficacy and safety of mecapegfilgrastim for prophylaxis of chemotherapy-induced neutropenia in patients with breast cancer: a randomized, multicenter, active-controlled phase III trial. Ann Transl Med 2019;7:482. [PMID: 31700918 DOI: 10.21037/atm.2019.07.95] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
79 van Steenhoven JEC, Kuijer A, van Maaren MC, Roos M, Elias SG, van Diest PJ, Siesling S, Smidt ML, Boersma LJ, van Dalen T. Quantifying the Mitigating Effects of Whole-Breast Radiotherapy and Systemic Treatments on Regional Recurrence Incidence Among Breast Cancer Patients. Ann Surg Oncol 2020;27:3402-11. [PMID: 32198570 DOI: 10.1245/s10434-020-08356-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
80 Kallel M, Elloumi F, Khabir A, Ghorbal L, Chaabouni S, Amouri H, Frikha M, Daoud J. Breast cancer in young women in southern Tunisia: Anatomical study and clinical prognostic factors: About a series of 83 patients. Rep Pract Oncol Radiother 2015;20:155-60. [PMID: 25949218 DOI: 10.1016/j.rpor.2015.01.007] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
81 Giordano SH, Duan Z, Kuo YF, Hortobagyi GN, Freeman J, Goodwin JS. Impact of a scientific presentation on community treatment patterns for primary breast cancer. J Natl Cancer Inst 2006;98:382-8. [PMID: 16537830 DOI: 10.1093/jnci/djj090] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 2.0] [Reference Citation Analysis]
82 Kiba T, Morii N, Takahashi H, Ozaki S, Atsumi M, Masumoto F, Yamashiro H. Pathological response rate in hormone-positive breast cancer patients treated with neoadjuvant FEC and triweekly docetaxel: a case series. Breast Cancer (Dove Med Press) 2015;7:245-50. [PMID: 26357489 DOI: 10.2147/BCTT.S90975] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
83 Isakoff SJ. Triple-negative breast cancer: role of specific chemotherapy agents. Cancer J 2010;16:53-61. [PMID: 20164691 DOI: 10.1097/PPO.0b013e3181d24ff7] [Cited by in Crossref: 184] [Cited by in F6Publishing: 105] [Article Influence: 16.7] [Reference Citation Analysis]
84 Blum JL, Flynn PJ, Yothers G, Asmar L, Geyer CE Jr, Jacobs SA, Robert NJ, Hopkins JO, O'Shaughnessy JA, Dang CT, Gómez HL, Fehrenbacher L, Vukelja SJ, Lyss AP, Paul D, Brufsky AM, Jeong JH, Colangelo LH, Swain SM, Mamounas EP, Jones SE, Wolmark N. Anthracyclines in Early Breast Cancer: The ABC Trials-USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 (NRG Oncology). J Clin Oncol 2017;35:2647-55. [PMID: 28398846 DOI: 10.1200/JCO.2016.71.4147] [Cited by in Crossref: 109] [Cited by in F6Publishing: 52] [Article Influence: 27.3] [Reference Citation Analysis]
85 Krendyukov A, Schiestl M, Höbel N, Aapro M. Clinical equivalence with G-CSF biosimilars: methodologic approach in a (neo)adjuvant setting in non-metastatic breast cancer. Support Care Cancer 2018;26:33-40. [PMID: 28929372 DOI: 10.1007/s00520-017-3861-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
86 Yadav BS, Sharma SC, Chanana P, Jhamb S. Systemic treatment strategies for triple-negative breast cancer. World J Clin Oncol 2014;5:125-33. [PMID: 24829859 DOI: 10.5306/wjco.v5.i2.125] [Cited by in CrossRef: 72] [Cited by in F6Publishing: 65] [Article Influence: 10.3] [Reference Citation Analysis]
87 Barcenas CH, Niu J, Zhang N, Zhang Y, Buchholz TA, Elting LS, Hortobagyi GN, Smith BD, Giordano SH. Risk of hospitalization according to chemotherapy regimen in early-stage breast cancer. J Clin Oncol 2014;32:2010-7. [PMID: 24868022 DOI: 10.1200/JCO.2013.49.3676] [Cited by in Crossref: 75] [Cited by in F6Publishing: 28] [Article Influence: 10.7] [Reference Citation Analysis]
88 Loibl S. New Therapeutic Options for Breast Cancer during Pregnancy. Breast Care (Basel) 2008;3:171-6. [PMID: 20824035 DOI: 10.1159/000136002] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
89 Mamounas EP, Tang G, Paik S, Baehner FL, Liu Q, Jeong JH, Kim SR, Butler SM, Jamshidian F, Cherbavaz DB, Sing AP, Shak S, Julian TB, Lembersky BC, Lawrence Wickerham D, Costantino JP, Wolmark N. 21-Gene Recurrence Score for prognosis and prediction of taxane benefit after adjuvant chemotherapy plus endocrine therapy: results from NSABP B-28/NRG Oncology. Breast Cancer Res Treat 2018;168:69-77. [PMID: 29128898 DOI: 10.1007/s10549-017-4550-8] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
90 Yeo W, Pang E, Liem GS, Suen JJS, Ng RYW, Yip CCH, Li L, Yip CHW, Mo FKF. Menopausal symptoms in relationship to breast cancer-specific quality of life after adjuvant cytotoxic treatment in young breast cancer survivors. Health Qual Life Outcomes 2020;18:24. [PMID: 32041627 DOI: 10.1186/s12955-020-1283-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
91 Anampa J, Makower D, Sparano JA. Progress in adjuvant chemotherapy for breast cancer: an overview. BMC Med 2015;13:195. [PMID: 26278220 DOI: 10.1186/s12916-015-0439-8] [Cited by in Crossref: 134] [Cited by in F6Publishing: 114] [Article Influence: 22.3] [Reference Citation Analysis]
92 Shaikh AY, Shih JA. Chemotherapy-induced cardiotoxicity. Curr Heart Fail Rep. 2012;9:117-127. [PMID: 22382639 DOI: 10.1007/s11897-012-0083-y] [Cited by in Crossref: 39] [Cited by in F6Publishing: 29] [Article Influence: 4.3] [Reference Citation Analysis]
93 Lee KH, Im SA, Oh DY, Lee SH, Chie EK, Han W, Kim DW, Kim TY, Park IA, Noh DY, Heo DS, Ha SW, Bang YJ. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy. BMC Cancer 2007;7:63. [PMID: 17430582 DOI: 10.1186/1471-2407-7-63] [Cited by in Crossref: 48] [Cited by in F6Publishing: 48] [Article Influence: 3.4] [Reference Citation Analysis]
94 Suzuki T, Toi M, Saji S, Horiguchi K, Aruga T, Suzuki E, Horiguchi S, Funata N, Karasawa K, Kamata N. Early breast cancer. Int J Clin Oncol 2006;11:108-19. [PMID: 16622745 DOI: 10.1007/s10147-006-0564-7] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
95 De Ligio JT, Velkova A, Zorio DA, Monteiro AN. Can the status of the breast and ovarian cancer susceptibility gene 1 product (BRCA1) predict response to taxane-based cancer therapy? Anticancer Agents Med Chem 2009;9:543-9. [PMID: 19519295 DOI: 10.2174/187152009788451798] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
96 Zhou WB, Yin H, Liu XA, Zha XM, Chen L, Dai JC, Tao AD, Chen L, Ma JJ, Ling LJ, Wang S. Incidence of chemotherapy-induced amenorrhea associated with epirubicin, docetaxel and navelbine in younger breast cancer patients. BMC Cancer 2010;10:281. [PMID: 20540745 DOI: 10.1186/1471-2407-10-281] [Cited by in Crossref: 25] [Cited by in F6Publishing: 16] [Article Influence: 2.3] [Reference Citation Analysis]
97 Mittmann N, Verma S, Koo M, Alloul K, Trudeau M. Cost effectiveness of TAC versus FAC in adjuvant treatment of node-positive breast cancer. Curr Oncol 2010;17:7-16. [PMID: 20179798 DOI: 10.3747/co.v17i1.445] [Cited by in Crossref: 4] [Cited by in F6Publishing: 10] [Article Influence: 0.4] [Reference Citation Analysis]
98 Bernard LM, Verma S, Thompson MF, Chan BC, Mittmann N, Asma L, Jones SE. A Canadian economic analysis of U.S. Oncology Adjuvant Trial 9735. Curr Oncol 2011;18:67-75. [PMID: 21505597 DOI: 10.3747/co.v18i2.701] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
99 Mirzaei HR, Sabet Rasekh P, Nasrollahi F, Sabet Rasekh P, Akbari Tirabad Z, Moein HR, Ghaffari Pour T, Hajian P. Dose-dense epirubicin and cyclophosphamide followed by docetaxel as adjuvant chemotherapy in node-positive breast cancer. Int J Breast Cancer 2013;2013:404396. [PMID: 24187626 DOI: 10.1155/2013/404396] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
100 Sucheston LE, Zhao H, Yao S, Zirpoli G, Liu S, Barlow WE, Moore HC, Thomas Budd G, Hershman DL, Davis W, Ciupak GL, Stewart JA, Isaacs C, Hobday TJ, Salim M, Hortobagyi GN, Gralow JR, Livingston RB, Albain KS, Hayes DF, Ambrosone CB. Genetic predictors of taxane-induced neurotoxicity in a SWOG phase III intergroup adjuvant breast cancer treatment trial (S0221). Breast Cancer Res Treat 2011;130:993-1002. [PMID: 21766209 DOI: 10.1007/s10549-011-1671-3] [Cited by in Crossref: 51] [Cited by in F6Publishing: 46] [Article Influence: 5.1] [Reference Citation Analysis]
101 Fernandes R, Mazzarello S, Joy AA, Pond GR, Hilton J, Ibrahim MFK, Canil C, Ong M, Stober C, Vandermeer L, Hutton B, da Costa M, Damaraju S, Clemons M. Taxane acute pain syndrome (TAPS) in patients receiving chemotherapy for breast or prostate cancer: a prospective multi-center study. Support Care Cancer 2018;26:3073-81. [PMID: 29564623 DOI: 10.1007/s00520-018-4161-x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
102 Kühn T. Sentinel Lymph Node Biopsy in Early Breast Cancer. Breast Care (Basel) 2011;6:185-91. [PMID: 21779223 DOI: 10.1159/000329193] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
103 Emadi A, Jones RJ, Brodsky RA. Cyclophosphamide and cancer: golden anniversary. Nat Rev Clin Oncol. 2009;6:638-647. [PMID: 19786984 DOI: 10.1038/nrclinonc.2009.146] [Cited by in Crossref: 355] [Cited by in F6Publishing: 284] [Article Influence: 29.6] [Reference Citation Analysis]
104 Swain SM, Tang G, Geyer CE Jr, Rastogi P, Atkins JN, Donnellan PP, Fehrenbacher L, Azar CA, Robidoux A, Polikoff JA, Brufsky AM, Biggs DD, Levine EA, Zapas JL, Provencher L, Northfelt DW, Paik S, Costantino JP, Mamounas EP, Wolmark N. Definitive results of a phase III adjuvant trial comparing three chemotherapy regimens in women with operable, node-positive breast cancer: the NSABP B-38 trial. J Clin Oncol 2013;31:3197-204. [PMID: 23940225 DOI: 10.1200/JCO.2012.48.1275] [Cited by in Crossref: 88] [Cited by in F6Publishing: 40] [Article Influence: 11.0] [Reference Citation Analysis]
105 Barros-Gomes S, Herrmann J, Mulvagh SL, Lerman A, Lin G, Villarraga HR. Rationale for setting up a cardio-oncology unit: our experience at Mayo Clinic. Cardiooncology 2016;2:5. [PMID: 33530144 DOI: 10.1186/s40959-016-0014-2] [Cited by in Crossref: 18] [Cited by in F6Publishing: 8] [Article Influence: 3.6] [Reference Citation Analysis]
106 Jones JA, Avritscher EB, Cooksley CD, Michelet M, Bekele BN, Elting LS. Epidemiology of treatment-associated mucosal injury after treatment with newer regimens for lymphoma, breast, lung, or colorectal cancer. Support Care Cancer. 2006;14:505-515. [PMID: 16601950 DOI: 10.1007/s00520-006-0055-4] [Cited by in Crossref: 86] [Cited by in F6Publishing: 76] [Article Influence: 5.7] [Reference Citation Analysis]
107 Gandhi S, Fletcher GG, Eisen A, Mates M, Freedman OC, Dent SF, Trudeau ME. Adjuvant chemotherapy for early female breast cancer: a systematic review of the evidence for the 2014 Cancer Care Ontario systemic therapy guideline. Curr Oncol 2015;22:S82-94. [PMID: 25848343 DOI: 10.3747/co.22.2321] [Cited by in Crossref: 16] [Cited by in F6Publishing: 19] [Article Influence: 2.7] [Reference Citation Analysis]
108 Anders CK, Johnson R, Litton J, Phillips M, Bleyer A. Breast cancer before age 40 years. Semin Oncol. 2009;36:237-249. [PMID: 19460581 DOI: 10.1053/j.seminoncol.2009.03.001] [Cited by in Crossref: 369] [Cited by in F6Publishing: 278] [Article Influence: 30.8] [Reference Citation Analysis]
109 Corkery DP, Le Page C, Meunier L, Provencher D, Mes-Masson AM, Dellaire G. PRP4K is a HER2-regulated modifier of taxane sensitivity. Cell Cycle 2015;14:1059-69. [PMID: 25602630 DOI: 10.1080/15384101.2015.1007775] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
110 Montazeri A, Vahdaninia M, Harirchi I, Ebrahimi M, Khaleghi F, Jarvandi S. Quality of life in patients with breast cancer before and after diagnosis: an eighteen months follow-up study. BMC Cancer 2008;8:330. [PMID: 19014435 DOI: 10.1186/1471-2407-8-330] [Cited by in Crossref: 130] [Cited by in F6Publishing: 112] [Article Influence: 10.0] [Reference Citation Analysis]
111 Delgado-Sanz MC, García-Mendizábal MJ, Pollán M, Forjaz MJ, López-Abente G, Aragonés N, Pérez-Gómez B. Heath-related quality of life in Spanish breast cancer patients: a systematic review. Health Qual Life Outcomes 2011;9:3. [PMID: 21235770 DOI: 10.1186/1477-7525-9-3] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 2.9] [Reference Citation Analysis]
112 Yoo C, Kim SB, Ahn JH, Kim JE, Jung KH, Gong GY, Son BH, Ahn SH, Ahn SD, Kim HH, Shin HJ, Kim WK. A Randomized Phase II Trial of Capecitabine Plus Vinorelbine Followed by Docetaxel Versus Adriamycin Plus Cyclophosphamide Followed by Docetaxel as Neoadjuvant Chemotherapy for Breast Cancer. Cancer Res Treat 2015;47:406-15. [PMID: 25648092 DOI: 10.4143/crt.2014.073] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
113 Badache A, Gonçalves A. The ErbB2 signaling network as a target for breast cancer therapy. J Mammary Gland Biol Neoplasia 2006;11:13-25. [PMID: 16947083 DOI: 10.1007/s10911-006-9009-1] [Cited by in Crossref: 47] [Cited by in F6Publishing: 43] [Article Influence: 3.4] [Reference Citation Analysis]
114 Koutras A, Kalogeras KT, Wirtz RM, Alexopoulou Z, Bobos M, Zagouri F, Veltrup E, Timotheadou E, Gogas H, Pentheroudakis G, Pisanidis N, Magkou C, Christodoulou C, Bafaloukos D, Papakostas P, Aravantinos G, Pectasides D, Kalofonos HP, Fountzilas G. Evaluation of the prognostic significance of HER family mRNA expression in high-risk early breast cancer: a Hellenic Cooperative Oncology Group (HeCOG) validation study. J Transl Med 2015;13:171. [PMID: 26021752 DOI: 10.1186/s12967-015-0530-0] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
115 O'Sullivan CC, Ruddy KJ. Management of Potential Long-Term Toxicities in Breast Cancer Patients. Curr Breast Cancer Rep 2016;8:183-92. [PMID: 28503254 DOI: 10.1007/s12609-016-0229-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
116 Cardonick E. Pregnancy-associated breast cancer: optimal treatment options. Int J Womens Health. 2014;6:935-943. [PMID: 25395871 DOI: 10.2147/ijwh.s52381] [Cited by in Crossref: 21] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
117 Fehr MK, Welter J, Sell W, Jung R, Felberbaum R. Sensor-controlled scalp cooling to prevent chemotherapy-induced alopecia in female cancer patients. Curr Oncol 2016;23:e576-82. [PMID: 28050147 DOI: 10.3747/co.23.3200] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
118 Manchon P, Borràs JM, Ferro T, Espinàs JA; Breast Cancer OncoGuia Group. Breast Cancer OncoGuia. Clin Transl Oncol 2010;12:113-38. [PMID: 20156781 DOI: 10.1007/s12094-010-0477-9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
119 Fountzilas G, Dafni U, Papadimitriou C, Timotheadou E, Gogas H, Eleftheraki AG, Xanthakis I, Christodoulou C, Koutras A, Papandreou CN, Papakostas P, Miliaras S, Markopoulos C, Dimitrakakis C, Korantzopoulos P, Karanikiotis C, Bafaloukos D, Kosmidis P, Samantas E, Varthalitis I, Pavlidis N, Pectasides D, Dimopoulos MA. Dose-dense sequential adjuvant chemotherapy followed, as indicated, by trastuzumab for one year in patients with early breast cancer: first report at 5-year median follow-up of a Hellenic Cooperative Oncology Group randomized phase III trial. BMC Cancer 2014;14:515. [PMID: 25026897 DOI: 10.1186/1471-2407-14-515] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
120 Sakr H, Hamed RH, Anter AH, Yossef T. Sequential docetaxel as adjuvant chemotherapy for node-positive or/and T3 or T4 breast cancer: clinical outcome (Mansoura University). Med Oncol 2013;30:457. [PMID: 23322524 DOI: 10.1007/s12032-013-0457-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
121 Willson ML, Burke L, Ferguson T, Ghersi D, Nowak AK, Wilcken N. Taxanes for adjuvant treatment of early breast cancer. Cochrane Database Syst Rev 2019;9:CD004421. [PMID: 31476253 DOI: 10.1002/14651858.CD004421.pub3] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
122 Edwardson DW, Boudreau J, Mapletoft J, Lanner C, Kovala AT, Parissenti AM. Inflammatory cytokine production in tumor cells upon chemotherapy drug exposure or upon selection for drug resistance. PLoS One 2017;12:e0183662. [PMID: 28915246 DOI: 10.1371/journal.pone.0183662] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 5.5] [Reference Citation Analysis]
123 Zimmer AS, Steeg PS. Meaningful prevention of breast cancer metastasis: candidate therapeutics, preclinical validation, and clinical trial concerns. J Mol Med (Berl) 2015;93:13-29. [PMID: 25412774 DOI: 10.1007/s00109-014-1226-2] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
124 Tinker AV, Speers C, Barnett J, Olivotto IA, Chia S. Impact of a reduced dose intensity of adjuvant anthracycline based chemotherapy in a population-based cohort of stage I-II breast cancers. Ecancermedicalscience 2008;2:63. [PMID: 22275960 DOI: 10.3332/eCMS.2008.63] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
125 Kelly S, Wheatley D. Prevention of febrile neutropenia: use of granulocyte colony-stimulating factors. Br J Cancer 2009;101 Suppl 1:S6-10. [PMID: 19756005 DOI: 10.1038/sj.bjc.6605269] [Cited by in Crossref: 30] [Cited by in F6Publishing: 20] [Article Influence: 2.5] [Reference Citation Analysis]
126 Shen Y, Dong W, Feig BW, Ravdin P, Theriault RL, Giordano SH. Patterns of treatment for early stage breast cancers at the M. D. Anderson Cancer Center from 1997 to 2004. Cancer 2009;115:2041-51. [PMID: 19288569 DOI: 10.1002/cncr.24271] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
127 Aapro M, Crawford J, Kamioner D. Prophylaxis of chemotherapy-induced febrile neutropenia with granulocyte colony-stimulating factors: where are we now? Support Care Cancer 2010;18:529-41. [PMID: 20191292 DOI: 10.1007/s00520-010-0816-y] [Cited by in Crossref: 66] [Cited by in F6Publishing: 33] [Article Influence: 6.0] [Reference Citation Analysis]
128 Pajares B, Pollán M, Martín M, Mackey JR, Lluch A, Gavila J, Vogel C, Ruiz-Borrego M, Calvo L, Pienkowski T, Rodríguez-Lescure Á, Seguí MA, Tredan O, Antón A, Ramos M, Cámara Mdel C, Rodríguez-Martín C, Carrasco E, Alba E. Obesity and survival in operable breast cancer patients treated with adjuvant anthracyclines and taxanes according to pathological subtypes: a pooled analysis. Breast Cancer Res 2013;15:R105. [PMID: 24192331 DOI: 10.1186/bcr3572] [Cited by in Crossref: 41] [Cited by in F6Publishing: 43] [Article Influence: 5.1] [Reference Citation Analysis]
129 Gianni L, Gelber S, Ravaioli A, Price KN, Panzini I, Fantini M, Castiglione-Gertsch M, Pagani O, Simoncini E, Gelber RD, Coates AS, Goldhirsch A. Second non-breast primary cancer following adjuvant therapy for early breast cancer: a report from the International Breast Cancer Study Group. Eur J Cancer 2009;45:561-71. [PMID: 19062268 DOI: 10.1016/j.ejca.2008.10.011] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
130 Hangai S, Iwase S, Kawaguchi T, Kogure Y, Miyaji T, Matsunaga T, Nagumo Y, Yamaguchi T. Effect of active hexose-correlated compound in women receiving adjuvant chemotherapy for breast cancer: a retrospective study. J Altern Complement Med 2013;19:905-10. [PMID: 23829813 DOI: 10.1089/acm.2012.0914] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
131 Swaroop MN, Ferguson CM, Horick NK, Skolny MN, Miller CL, Jammallo LS, Brunelle CL, O'Toole JA, Isakoff SJ, Specht MC, Taghian AG. Impact of adjuvant taxane-based chemotherapy on development of breast cancer-related lymphedema: results from a large prospective cohort. Breast Cancer Res Treat 2015;151:393-403. [PMID: 25940996 DOI: 10.1007/s10549-015-3408-1] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 5.3] [Reference Citation Analysis]
132 Bernhard J, Zahrieh D, Zhang JJ, Martinelli G, Basser R, Hürny C, Forbes JF, Aebi S, Yeo W, Thürlimann B, Green MD, Colleoni M, Gelber RD, Castiglione-Gertsch M, Price KN, Goldhirsch A, Coates AS; International Breast Cancer Study Group. Quality of life and quality-adjusted survival (Q-TWiST) in patients receiving dose-intensive or standard dose chemotherapy for high-risk primary breast cancer. Br J Cancer 2008;98:25-33. [PMID: 18043579 DOI: 10.1038/sj.bjc.6604092] [Cited by in Crossref: 16] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
133 Younis T, Rayson D, Thompson K. Primary G-CSF prophylaxis for adjuvant TC or FEC-D chemotherapy outside of clinical trial settings: a systematic review and meta-analysis. Support Care Cancer 2012;20:2523-30. [PMID: 22252548 DOI: 10.1007/s00520-011-1375-6] [Cited by in Crossref: 39] [Cited by in F6Publishing: 25] [Article Influence: 4.3] [Reference Citation Analysis]
134 Giuliano AE, Ballman K, McCall L, Beitsch P, Whitworth PW, Blumencranz P, Leitch AM, Saha S, Morrow M, Hunt KK. Locoregional Recurrence After Sentinel Lymph Node Dissection With or Without Axillary Dissection in Patients With Sentinel Lymph Node Metastases: Long-term Follow-up From the American College of Surgeons Oncology Group (Alliance) ACOSOG Z0011 Randomized Trial. Ann Surg. 2016;264:413-420. [PMID: 27513155 DOI: 10.1097/sla.0000000000001863] [Cited by in Crossref: 243] [Cited by in F6Publishing: 78] [Article Influence: 60.8] [Reference Citation Analysis]
135 Crozier JA, Swaika A, Moreno-Aspitia A. Adjuvant chemotherapy in breast cancer: To use or not to use, the anthracyclines. World J Clin Oncol 2014;5:529-38. [PMID: 25114866 DOI: 10.5306/wjco.v5.i3.529] [Cited by in CrossRef: 40] [Cited by in F6Publishing: 33] [Article Influence: 5.7] [Reference Citation Analysis]
136 Zhang F, Drabier R. IPAD: the Integrated Pathway Analysis Database for Systematic Enrichment Analysis. BMC Bioinformatics 2012;13 Suppl 15:S7. [PMID: 23046449 DOI: 10.1186/1471-2105-13-S15-S7] [Cited by in Crossref: 35] [Cited by in F6Publishing: 22] [Article Influence: 3.9] [Reference Citation Analysis]
137 Grushko TA, Filiaci VL, Mundt AJ, Ridderstråle K, Olopade OI, Fleming GF; Gynecologic Oncology Group. An exploratory analysis of HER-2 amplification and overexpression in advanced endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2008;108:3-9. [PMID: 17945336 DOI: 10.1016/j.ygyno.2007.09.007] [Cited by in Crossref: 95] [Cited by in F6Publishing: 73] [Article Influence: 6.8] [Reference Citation Analysis]
138 Koizumi W, Kim YH, Fujii M, Kim HK, Imamura H, Lee KH, Hara T, Chung HC, Satoh T, Cho JY. Addition of docetaxel to S-1 without platinum prolongs survival of patients with advanced gastric cancer: a randomized study (START). J Cancer Res Clin Oncol. 2014;140:319-328. [PMID: 24366758 DOI: 10.1007/s00432- 013-1563-5] [Reference Citation Analysis]
139 Smith I, Chua S. Medical treatment of early breast cancer. III: chemotherapy. BMJ 2006;332:161-2. [PMID: 16424494 DOI: 10.1136/bmj.332.7534.161] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
140 Swain SM, Land SR, Ritter MW, Costantino JP, Cecchini RS, Mamounas EP, Wolmark N, Ganz PA. Amenorrhea in premenopausal women on the doxorubicin-and-cyclophosphamide-followed-by-docetaxel arm of NSABP B-30 trial. Breast Cancer Res Treat 2009;113:315-20. [PMID: 18302020 DOI: 10.1007/s10549-008-9937-0] [Cited by in Crossref: 79] [Cited by in F6Publishing: 60] [Article Influence: 6.1] [Reference Citation Analysis]
141 Ganz PA, Land SR, Geyer CE Jr, Cecchini RS, Costantino JP, Pajon ER, Fehrenbacher L, Atkins JN, Polikoff JA, Vogel VG, Erban JK, Livingston RB, Perez EA, Mamounas EP, Wolmark N, Swain SM. Menstrual history and quality-of-life outcomes in women with node-positive breast cancer treated with adjuvant therapy on the NSABP B-30 trial. J Clin Oncol 2011;29:1110-6. [PMID: 21300930 DOI: 10.1200/JCO.2010.29.7689] [Cited by in Crossref: 82] [Cited by in F6Publishing: 31] [Article Influence: 8.2] [Reference Citation Analysis]
142 Sparano JA, Wang M, Martino S, Jones V, Perez EA, Saphner T, Wolff AC, Sledge GW, Wood WC, Davidson NE. Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med. 2008;358:1663-1671. [PMID: 18420499 DOI: 10.1056/nejmoa0707056] [Cited by in Crossref: 617] [Cited by in F6Publishing: 207] [Article Influence: 47.5] [Reference Citation Analysis]
143 Chaillou T, McPeek A, Lanner JT. Docetaxel does not impair skeletal muscle force production in a murine model of cancer chemotherapy. Physiol Rep 2017;5:e13261. [PMID: 28583990 DOI: 10.14814/phy2.13261] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
144 Ma L, Sato F, Sato R, Matsubara T, Hirai K, Yamasaki M, Shin T, Shimada T, Nomura T, Mori K, Sumino Y, Mimata H. Dual targeting of heat shock proteins 90 and 70 promotes cell death and enhances the anticancer effect of chemotherapeutic agents in bladder cancer. Oncol Rep 2014;31:2482-92. [PMID: 24718854 DOI: 10.3892/or.2014.3132] [Cited by in Crossref: 37] [Cited by in F6Publishing: 32] [Article Influence: 5.3] [Reference Citation Analysis]
145 Hickey M, Peate M, Saunders CM, Friedlander M. Breast cancer in young women and its impact on reproductive function. Hum Reprod Update. 2009;15:323-339. [PMID: 19174449 DOI: 10.1093/humupd/dmn064] [Cited by in Crossref: 85] [Cited by in F6Publishing: 78] [Article Influence: 7.1] [Reference Citation Analysis]
146 Wolff AC, Blackford AL, Visvanathan K, Rugo HS, Moy B, Goldstein LJ, Stockerl-Goldstein K, Neumayer L, Langbaum TS, Theriault RL, Hughes ME, Weeks JC, Karp JE. Risk of marrow neoplasms after adjuvant breast cancer therapy: the national comprehensive cancer network experience. J Clin Oncol 2015;33:340-8. [PMID: 25534386 DOI: 10.1200/JCO.2013.54.6119] [Cited by in Crossref: 60] [Cited by in F6Publishing: 29] [Article Influence: 8.6] [Reference Citation Analysis]
147 Debled M, Houédé N, Madranges N, Donamaria C, Floquet A, Durand M, Mauriac L. Does chemotherapy-induced neutropaenia result in a postponement of adjuvant or neoadjuvant regimens in breast cancer patients? Results of a retrospective analysis. Br J Cancer 2007;97:1642-7. [PMID: 18000502 DOI: 10.1038/sj.bjc.6604094] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
148 Ji Y, Li S, Zhang X, Liu Y, Lu Q, Li Q, Chen W, Sheng J, Jiang K, Liang H, Sha S, Li M, Chen Z, Zheng P, Wang M, Feng Y, Wang L, Wu H, Liu H, Huang Y, Yin Z, Xue X. The prophylactic and therapeutic effects of moxibustion combined with traditional Chinese medicine decoction for treating chemotherapy-induced myelosuppression in early-stage breast cancer: study protocol for a randomized controlled trial. Trials 2020;21:844. [PMID: 33046128 DOI: 10.1186/s13063-020-04749-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
149 Wang F, Dai W, Wang Y, Shen M, Chen K, Cheng P, Zhang Y, Wang C, Li J, Zheng Y, Lu J, Yang J, Zhu R, Zhang H, Zhou Y, Xu L, Guo C. The synergistic in vitro and in vivo antitumor effect of combination therapy with salinomycin and 5-fluorouracil against hepatocellular carcinoma. PLoS One 2014;9:e97414. [PMID: 24816638 DOI: 10.1371/journal.pone.0097414] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 4.1] [Reference Citation Analysis]
150 Lambertini M, Anserini P, Levaggi A, Poggio F, Del Mastro L. Fertility counseling of young breast cancer patients. J Thorac Dis 2013;5 Suppl 1:S68-80. [PMID: 23819030 DOI: 10.3978/j.issn.2072-1439.2013.05.22] [Cited by in F6Publishing: 9] [Reference Citation Analysis]
151 Bear HD, Tang G, Rastogi P, Geyer CE Jr, Robidoux A, Atkins JN, Baez-Diaz L, Brufsky AM, Mehta RS, Fehrenbacher L, Young JA, Senecal FM, Gaur R, Margolese RG, Adams PT, Gross HM, Costantino JP, Swain SM, Mamounas EP, Wolmark N. Bevacizumab added to neoadjuvant chemotherapy for breast cancer. N Engl J Med. 2012;366:310-320. [PMID: 22276821 DOI: 10.1056/nejmoa1111097] [Cited by in Crossref: 322] [Cited by in F6Publishing: 149] [Article Influence: 35.8] [Reference Citation Analysis]
152 Anders C, Marcom PK, Peterson B, Gu L, Unruhe S, Welch R, Lyons P, Behera M, Copland S, Kimmick G, Shaw H, Snyder S, Antenos M, Woodruff T, Blackwell K. A pilot study of predictive markers of chemotherapy-related amenorrhea among premenopausal women with early stage breast cancer. Cancer Invest 2008;26:286-95. [PMID: 18317970 DOI: 10.1080/07357900701829777] [Cited by in Crossref: 84] [Cited by in F6Publishing: 78] [Article Influence: 6.5] [Reference Citation Analysis]
153 Liubao P, Xiaomin W, Chongqing T, Karnon J, Gannong C, Jianhe L, Wei C, Xia L, Junhua C. Cost-effectiveness analysis of adjuvant therapy for operable breast cancer from a Chinese perspective: doxorubicin plus cyclophosphamide versus docetaxel plus cyclophosphamide. Pharmacoeconomics 2009;27:873-86. [PMID: 19803541 DOI: 10.2165/11314750-000000000-00000] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 2.4] [Reference Citation Analysis]
154 Lopes F, Smith R, Anderson RA, Spears N. Docetaxel induces moderate ovarian toxicity in mice, primarily affecting granulosa cells of early growing follicles. Mol Hum Reprod 2014;20:948-59. [PMID: 25080441 DOI: 10.1093/molehr/gau057] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 3.7] [Reference Citation Analysis]
155 Maltaris T, Weigel M, Mueller A, Schmidt M, Seufert R, Fischl F, Koelbl H, Dittrich R. Cancer and fertility preservation: fertility preservation in breast cancer patients. Breast Cancer Res 2008;10:206. [PMID: 18492214 DOI: 10.1186/bcr1991] [Cited by in Crossref: 39] [Cited by in F6Publishing: 27] [Article Influence: 3.0] [Reference Citation Analysis]
156 Gronich N, Lavi I, Barnett-Griness O, Saliba W, Abernethy DR, Rennert G. Tyrosine kinase-targeting drugs-associated heart failure. Br J Cancer 2017;116:1366-73. [PMID: 28399109 DOI: 10.1038/bjc.2017.88] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 3.5] [Reference Citation Analysis]
157 Goldstein LJ, O'Neill A, Sparano JA, Perez EA, Shulman LN, Martino S, Davidson NE. Concurrent doxorubicin plus docetaxel is not more effective than concurrent doxorubicin plus cyclophosphamide in operable breast cancer with 0 to 3 positive axillary nodes: North American Breast Cancer Intergroup Trial E 2197. J Clin Oncol 2008;26:4092-9. [PMID: 18678836 DOI: 10.1200/JCO.2008.16.7841] [Cited by in Crossref: 74] [Cited by in F6Publishing: 28] [Article Influence: 5.7] [Reference Citation Analysis]
158 Colleoni M, Cole BF, Viale G, Regan MM, Price KN, Maiorano E, Mastropasqua MG, Crivellari D, Gelber RD, Goldhirsch A, Coates AS, Gusterson BA. Classical cyclophosphamide, methotrexate, and fluorouracil chemotherapy is more effective in triple-negative, node-negative breast cancer: results from two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer. J Clin Oncol 2010;28:2966-73. [PMID: 20458051 DOI: 10.1200/JCO.2009.25.9549] [Cited by in Crossref: 105] [Cited by in F6Publishing: 41] [Article Influence: 9.5] [Reference Citation Analysis]
159 Palmieri FM, Perez EA. Managing high-risk breast cancer. Semin Oncol Nurs 2007;23:29-36. [PMID: 17303514 DOI: 10.1016/j.soncn.2006.11.005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
160 Aubele M, Schmitt M, Napieralski R, Paepke S, Ettl J, Absmaier M, Magdolen V, Martens J, Foekens JA, Wilhelm OG, Kiechle M. The Predictive Value of PITX2 DNA Methylation for High-Risk Breast Cancer Therapy: Current Guidelines, Medical Needs, and Challenges. Dis Markers 2017;2017:4934608. [PMID: 29138528 DOI: 10.1155/2017/4934608] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
161 Shen Y, Fujii T, Ueno NT, Tripathy D, Fu N, Zhou H, Ning J, Xiao L. Comparative efficacy of adjuvant trastuzumab-containing chemotherapies for patients with early HER2-positive primary breast cancer: a network meta-analysis. Breast Cancer Res Treat 2019;173:1-9. [PMID: 30242579 DOI: 10.1007/s10549-018-4969-6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]